Hanmi Pharm applies for U.S. approval new biologic ‘Rolontis’ in 4th quarter
Hanmi Pharm is expected to apply for commercialization approval for a new biologic developed by Hanmi Pharm(CEO Sae-Chang Kwon and Jong-Soo Woo) for the treatment of persistent neutropenia, Rolontis, in the U.S. this 4th quarter.
In a press release, U.S. Spectrum Pharmaceuticals, a Hanmi Pharm’s...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
